MedicalNewsToday reports that "NICE (National Institute for Clinical Excellence) in the UK has decided not to recommend Lucentis (ranibizumab) for diabetic macular edema
(British spelling: oedema) treatment. NICE approves or turns down
treatments that will be covered by the NHS (National Health Service),
the UK's universal health care system. Patients will still be able to
get Lucentis prescriptions for diabetic macular edema, but at a much
higher personal cost (private prescription)." Read more.
No comments:
Post a Comment